JWH-210 Wikipedia: Revision history

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

curprev 09:3109:31, 24 May 2026 DamonAngas210 talk contribs m 6,294 bytes −1,694 No edit summary undo
curprev 09:2809:28, 24 May 2026 DamonAngas210 talk contribs m 7,988 bytes +2,217 No edit summary undo

curprev 12:1912:19, 22 May 2026 DamonAngas210 talk contribs m 5,771 bytes −742 No edit summary undo
curprev 12:1612:16, 22 May 2026 DamonAngas210 talk contribs m 6,513 bytes +1,216 No edit summary undo
curprev 12:1512:15, 22 May 2026 DamonAngas210 talk contribs m 5,297 bytes −415 No edit summary undo

curprev 07:5707:57, 18 May 2026 Adelaida13D talk contribs m 5,712 bytes +379 No edit summary undo
curprev 07:5607:56, 18 May 2026 Norris9662 talk contribs m 5,333 bytes +21 No edit summary undo
curprev 07:1307:13, 18 May 2026 DamonAngas210 talk contribs m 5,312 bytes −140 No edit summary undo

curprev 09:1309:13, 15 May 2026 GeraldineJudd1 talk contribs 5,452 bytes +5,452 Created page with "The % peak area abundance ratio of metabolites detected in the urine samples are often affected by numerous factors such as drug intake behaviour (intake route, amount of drug and intake frequency), time from last drug intake and metabolic stability. This indicated that the phase I metabolism of 4F-MDMB-BINACA are unlikely to be affected significantly by polydrug intake. Oxidative defluorination with subsequent butanoic acid formation (B17) metabolite, the second major m..."

24 May 2026

22 May 2026

18 May 2026

15 May 2026